Skip to content

Free cash flow at other companies

Medtronic logo
MedtronicMDT
$2.09B+0.8%
Haemonetics logo
HaemoneticsHAE
$53.28M-47.2%
CorMedix logo
CorMedixCRMD
$41.65M+111%
Teladoc Health logo
Teladoc HealthTDOC
$7.86M-40.5%
DaVita logo
DaVitaDVA
Tenet Healthcare logo
Tenet HealthcareTHC

Other financials

Income statement

See full
Revenue$27.9M-6.3%
Gross profit$12.1M+9.3%
Operating income-$16.9M-3.2%
Net income-$19.0M+26.4%
EPS (diluted)-$1.03+71.9%

Balance sheet

See full
Cash & equivalents$30.6M-59.7%
Total debt$101.6M+3.5%
Total equity$111.7M-34.3%
Total assets$249.5M-17.2%

Cash flow

See full
Operating cash flow-$12.8M+50.0%
CapEx$65.0K-47.2%

Valuation

See full
Market cap$80.08M-77.6%
Enterprise value$151.13M-63.6%
P/S0.7×-2.3×

Profitability

See full
Gross margin40.6%+4.7pp
Operating margin-57.2%-12.9pp
Net margin-63.7%-16.7pp
FCF margin-29.1%-11.5pp

Returns & leverage

See full
Return on equity-53.2%-14.8pp
Debt / equity0.9×+0.3×
Current ratio6.3×-2.1×

Where this comes from

Calculated from Outset Medical, Inc.’s reported figures.

The official record: Outset Medical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Outset Medical, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Outset Medical, Inc.'s free cash flow?
Outset Medical, Inc. (OM) reported free cash flow of -$12.91M in Q1 2026.
How has Outset Medical, Inc.'s free cash flow changed year-over-year?
Outset Medical, Inc.'s free cash flow increased by 49.9% year-over-year, from -$25.79M to -$12.91M.
What is the long-term trend for Outset Medical, Inc.'s free cash flow?
Over 4 years (2021 to 2025), Outset Medical, Inc.'s free cash flow has grown at a -22.9% compound annual growth rate (CAGR), from -$133.37M to -$47.13M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.